Anti-retroviral treatment interruptions in HIV-infected adults: Causes, clinical, immunological and virological consequences;Étude rétrospective descriptive évaluant les causes et les conséquences cliniques, immunologiques et virologiques des interruptions de traitement antirétroviral chez des adultes infectés par le VIH-1

Revue de Medecine Interne

Volumn 24, Issue 6, 2003, Pages 350-357

  Sommet, A ^a   Delpierre, C ^a   Cuzin, L ^a   Jaafar, A ^a   Marchou, B ^a   Massip, B ^a  

^a CHU PURPAN   (France)

Author keywords

Antiretroviral therapy; Compliance; Drug toxicity; Treatment failure; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL FEATURE; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; T LYMPHOCYTE; TREATMENT FAILURE; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG COMBINATION; DRUG THERAPY; HETEROSEXUALITY; HOMOSEXUALITY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 0038141770     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00067-5     Document Type: Article

References (33)

1. Hogg RS, O'Shaughnessy M, Gataric N, Yip B, Craib K, Schechter M, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294.
2. Palella F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
3. Mocroft A, Vella S, Benfield T, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
4. Sollitto S, Mehlman M, Youngner S, Lederman MM. Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment? AIDS 2001;15:153-9.
5. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
6. Vanhove G, Schapiro J, Winters M, Merigan T, Blaschke T. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996;276:1955-6.
7. Harrigan RP, Whaley M, Montaner JS. Rate of HIV-1 rebound upon stopping antiretroviral therapy. AIDS 1999;13:F59-62.
8. Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, et al. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol 1999;59: 507-11.
9. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000;14: 397-403.
10. Garcia F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999;13:F79-86.
11. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-127.
12. Verhofstede C, van Wanzeele F, van der Gucht B, de Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor sensitive genotype. AIDS 1999;13:2541-6.
13. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14:2857-67.
14. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic effects of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-80.
15. Izopet J, Massip P, Souyris C, Sandres K, Puissant B, Obadia M, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000;14:2247-55.
16. Papasavvas E, Ortiz G, Gross R, Sun J, Moore E, Heymann J, et al. Enhancement of human immunodeficiency virus type1-specific CD4 and CD8 cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000; 182:766-75.
17. Davey R, Bhat N, Yoder C, Chun T, Metcalf J, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-14.
18. Haslett P, Nixon D, Shen Z, Larsson M, Cox W, Manandhar R, et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-VIH chemotherapy. J Infect Dis 2000;181: 1264-72.
19. Hatano H, Miller K, Yoder C, Yanovski J, Sebring N, Jones E, et al. Metabolic and anthropometric consequences of interruption of highlyactive antiretroviral therapy. AIDS 2000;14:1935-42.
20. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340:1683-4.
21. Ortiz G, Nixon D, Trkola A, Binley J, Jin X, Bonhoeffer S, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999;104:R13-18.
22. Youle M, Janossy G, Turnbull W, Tilling R, Loveday C, Mocroft A, et al. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. AIDS 2000;14:1717-20.
23. Colven R, Harrington R, Spach D, Cohen C, Hooton T. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Ann Intern Med 2000; 133:430-4.
24. Kilby J, Goepfert P, Miller A, Gnann JJ, Sillers M, Saag M, et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med 2000;133:435-8.
25. D'Arminio Monforte A, Cozzi Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000;14:499-507.
26. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment center. AIDS 2001;15:185-94.
27. Delfraissy J. Prise en charge des personnes infectées par le VIH-Recommandations du groupe d'experts. Paris: Flammarion Médecine-Sciences; 2002.
28. De Jong M, de Boer R, de Wolf F, Foudraine N, Boucher CA, Goudsmit J, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997;11:F79-84.
29. Neumann A, Tubiana R, Calvez V, Robert C, Li T-S, Agut H, et al. HIV-1 rebound during interruption of highly antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 1999;13:677-83.
30. Goudsmit J, De Ronde A, Ho D, Perelson A. Human immunodeficiencyvirus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996;70:5662-4.
31. Goudsmit J, de Ronde A, de Rooij E, de Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type I subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 1997; 71: 4479-84.
32. Garcia F, Plana M, Ortiz G, Bonhoeffer S, Soriano A, Vidal C, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15: F29-40.
33. Cuzin L, Pugliese P, Enel P, Agher R, Alfandari S, Billaud E, et al. The Nadis 2000 project: developpement of an electronic medical record for patients living with HIV, HBV, or HCV. In: XIth Symposium on HIV Infection. Toulon, 14-16 Juin 2001.